Wesley T Beaulieu1, Neil M Bressler2, Michele Melia3, Cynthia Owsley4, Calvin E Mein5, Jeffrey G Gross6, Lee M Jampol7, Adam R Glassman3. 1. Jaeb Center for Health Research, Tampa, Florida. Electronic address: drcrstat8@jaeb.org. 2. Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Jaeb Center for Health Research, Tampa, Florida. 4. Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, Alabama. 5. Retinal Consultants of San Antonio, San Antonio, Texas. 6. Carolina Retina Center PA, Columbia, South Carolina. 7. Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Abstract
PURPOSE: To compare patient-centered outcomes in patients with proliferative diabetic retinopathy (PDR) treated withranibizumab vs panretinal photocoagulation (PRP). DESIGN: Randomized clinical trial. METHODS: Setting: Multicenter (55 U.S. sites). PATIENT POPULATION: Total of 216 adults with 1 study eye out of 305 adults (excluding participants with 2 study eyes, because each eye received a different treatment) with PDR, visual acuity 20/320 or better, no history of PRP. INTERVENTION: Ranibizumab (0.5 mg/0.05 mL) vs PRP. MAIN OUTCOME MEASURES: Change from baseline to 2 years in composite and prespecified subscale scores from the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25), University of Alabama Low Luminance Questionnaire (UAB-LLQ), and Work Productivity and Activity Impairment Questionnaire (WPAIQ). RESULTS: For the NEI VFQ-25 and UAB-LLQ composite scores, ranibizumab-PRP treatment group differences (95% CI) were +4.0 (-0.2, +8.3, P = .06) and +1.8 (-3.5, +7.1, P = 0.51) at 1 year, and +2.9 (-1.5, +7.2, P = .20) and +2.3 (-2.9, +7.5, P = .37) at 2 years, respectively. Work productivity loss measured with the WPAIQ was 15.6% less with ranibizumab (-26.3%, -4.8%, P = .005) at 1 year and 2.9% (-12.2%, +6.4%, P = .54) at 2 years. Eighty-three ranibizumab participants (97%) were 20/40 or better in at least 1 eye (visual acuity requirement to qualify for an unrestricted driver's license in many states) at 2 years compared with 82 PRP participants (87%, adjusted risk ratio = 1.1, 95% CI: 1.0, 1.2, P = .005). CONCLUSIONS: Though differences in some work productivity and driving-related outcomes favored ranibizumab over PRP, no differences between treatment regimens for PDR were identified for most of the other patient-centered outcomes considered.
RCT Entities:
PURPOSE: To compare patient-centered outcomes in patients with proliferative diabetic retinopathy (PDR) treated with ranibizumab vs panretinal photocoagulation (PRP). DESIGN: Randomized clinical trial. METHODS: Setting: Multicenter (55 U.S. sites). PATIENT POPULATION: Total of 216 adults with 1 study eye out of 305 adults (excluding participants with 2 study eyes, because each eye received a different treatment) with PDR, visual acuity 20/320 or better, no history of PRP. INTERVENTION: Ranibizumab (0.5 mg/0.05 mL) vs PRP. MAIN OUTCOME MEASURES: Change from baseline to 2 years in composite and prespecified subscale scores from the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25), University of Alabama Low Luminance Questionnaire (UAB-LLQ), and Work Productivity and Activity Impairment Questionnaire (WPAIQ). RESULTS: For the NEI VFQ-25 and UAB-LLQ composite scores, ranibizumab-PRP treatment group differences (95% CI) were +4.0 (-0.2, +8.3, P = .06) and +1.8 (-3.5, +7.1, P = 0.51) at 1 year, and +2.9 (-1.5, +7.2, P = .20) and +2.3 (-2.9, +7.5, P = .37) at 2 years, respectively. Work productivity loss measured with the WPAIQ was 15.6% less with ranibizumab (-26.3%, -4.8%, P = .005) at 1 year and 2.9% (-12.2%, +6.4%, P = .54) at 2 years. Eighty-three ranibizumabparticipants (97%) were 20/40 or better in at least 1 eye (visual acuity requirement to qualify for an unrestricted driver's license in many states) at 2 years compared with 82 PRP participants (87%, adjusted risk ratio = 1.1, 95% CI: 1.0, 1.2, P = .005). CONCLUSIONS: Though differences in some work productivity and driving-related outcomes favored ranibizumab over PRP, no differences between treatment regimens for PDR were identified for most of the other patient-centered outcomes considered.
Authors: Neil M Bressler; Rohit Varma; Ivan J Suñer; Chantal M Dolan; James Ward; Jason S Ehrlich; Shoshana Colman; Adam Turpcu Journal: Ophthalmology Date: 2014-08-20 Impact factor: 12.079
Authors: Neil M Bressler; Tom S Chang; Ivan J Suñer; Jennifer T Fine; Chantal M Dolan; James Ward; Tsontcho Ianchulev Journal: Ophthalmology Date: 2010-03-02 Impact factor: 12.079
Authors: Neil M Bressler; Rohit Varma; Paul Mitchell; Ivan J Suñer; Chantal Dolan; James Ward; Alberto Ferreira; Jason S Ehrlich; Adam Turpcu Journal: JAMA Ophthalmol Date: 2016-02 Impact factor: 7.389